Arisan Therapeutics, Inc.
Arisan Therapeutics is a clinical stage company dedicated to discovering and developing novel solutions for the treatment of neglected and emerging infectious diseases. Their mission is to identify unmet medical needs and provide solutions through development, collaboration, and partnerships to benefit patients and defend against life-threatening infectious diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US-11548893-B2
View Details
Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US-11548893-B2
View DetailsProducts
Oral broad-spectrum arenavirus antiviral candidate (clinical-stage)
A small-molecule oral antiviral candidate developed as a broad-spectrum therapeutic for arenaviruses, advanced to Phase 1 clinical evaluation.
Preclinical filovirus inhibitor lead series
Lead compounds and chemical series identified for inhibition of filoviruses (Ebolavirus and related species), derived from structure-based design and medicinal chemistry programs.
Rapid point-of-care diagnostics for dengue and Zika (LSPR-based)
Rapid, sensitive point-of-care diagnostic tests under development for early detection of dengue and Zika virus infections using nanoplasmonic (LSPR) biosensor technology and antibody-based assays.
Oral broad-spectrum arenavirus antiviral candidate (clinical-stage)
A small-molecule oral antiviral candidate developed as a broad-spectrum therapeutic for arenaviruses, advanced to Phase 1 clinical evaluation.
Preclinical filovirus inhibitor lead series
Lead compounds and chemical series identified for inhibition of filoviruses (Ebolavirus and related species), derived from structure-based design and medicinal chemistry programs.
Rapid point-of-care diagnostics for dengue and Zika (LSPR-based)
Rapid, sensitive point-of-care diagnostic tests under development for early detection of dengue and Zika virus infections using nanoplasmonic (LSPR) biosensor technology and antibody-based assays.
Services
Collaborative discovery and optimization of small-molecule antiviral candidates, including medicinal chemistry, in vitro screening and in vivo efficacy studies.
Support for Phase I clinical studies and preparation of regulatory submissions to enable clinical progression of antiviral candidates.
Development of rapid, sensitive point-of-care diagnostics for viral pathogens and integration with mobile or field-deployable digital platforms.
Management and coordination of government-funded research programs and partnerships with defense and public health agencies.
Strategic IP management and compliance advisory services, including patent portfolio maintenance and FCOI policy implementation.
Collaborative discovery and optimization of small-molecule antiviral candidates, including medicinal chemistry, in vitro screening and in vivo efficacy studies.
Support for Phase I clinical studies and preparation of regulatory submissions to enable clinical progression of antiviral candidates.
Development of rapid, sensitive point-of-care diagnostics for viral pathogens and integration with mobile or field-deployable digital platforms.
Management and coordination of government-funded research programs and partnerships with defense and public health agencies.
Strategic IP management and compliance advisory services, including patent portfolio maintenance and FCOI policy implementation.
Expertise Areas
- Antiviral small-molecule drug discovery
- Preclinical development and animal efficacy models
- Phase 1 clinical development
- Point-of-care diagnostic development
Key Technologies
- Small-molecule oral therapeutics
- Structure-based drug design
- Computational chemistry
- Medicinal chemistry (SAR)
News & Updates
Westover JB, Naik S, Bailey KW, Wandersee L, Gantla VR, Hickerson BT, McCormack K, Henkel G, Gowen BB. Antiviral Res. (2022) Dec;208:105444.
Westover JB, Naik S, Bailey KW, Wandersee L, Gantla VR, Hickerson BT, McCormack K, Henkel G, Gowen BB. Antiviral Res. (2022) Dec;208:105444.